폐암 (NSCLC) | 바이오모아

ADCABiologicJanssen Research & Development,…Phase 3

Osimertinib (Osimertinib)

Carcinoma, Non-Small-Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 76.7%임상시험 88상태 RECRUITING

ADCCBiologicNovartis PharmaceuticalsdeliveryPhase 3

Trametinib (Trametinib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 100%임상시험 79상태 DISCONTINUED

ADCBiologicSWOG Cancer Research NetworksPhase 3

Afatinib Dimaleate (Afatinib Dimaleate)

Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 96%임상시험 59상태 RECRUITING

ADCBiologicPfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4

효능 ORR 75.3%임상시험 46상태 DISCONTINUED

CGTBiologicstaleNational Cancer Institute (NCI)Phase 1

Autologous B7-H3 CAR T (Autologous B7-H3 CAR T)

Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleEli LillyPhase 2

Cetuximab Sarotalocan Sodium (Cetuximab Sarotalocan Sodium)

Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

CGTBiologicstaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5

임상시험 1상태 RECRUITING

AntibodystaleZibo Municipal HospitalPhase 2

SBRT combined with Tislelizumab followed by Tislelizumab (SBRT combined with Tislelizumab followed by Tislelizumab)

NSCLC; Tislelizumab · FRα

#FR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING